HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Rule For Mandatory Supplement Registration Would Likely Give FDA Authority For Fines

ODSP Head Advises Stakeholders To Expect Congress To Open DSHEA

Executive Summary

“We would certainly want to have some enforcement and be able to utilize that enforcement,” says ODSP acting director Cara Welch. Stakeholders opposed to the change should “get comfortable with the idea of opening up DSHEA and should most certainly be part of the discussion.”

You may also be interested in...

AHPA Sees Pre-Market Approval Behind Legislation Titled ‘Mandatory Listing’ For Supplements In US

“FDA has all the authority it needs to enforce” regulations on supplement manufacturing, marketing and labeling, says AHPA president Michael McGuffin. “We're concerned that this will be a new pre-market registration requirement.” 

Sen. Durbin Will Introduce US Mandatory Supplement Registration Bill

Sen. Durbin has been a critic of FDA’s regulation of VMS product market regulation, putting him at odds with industry stakeholders. But “Dietary Supplement Listing Act” he and Sen. Braun will introduce later in week has support of CHPA and CRN.

FDA Request For Clarifying DSHEA, Like Mandatory Listing, Splits US Supplement Industry Groups

Already differing on supporting FDA suggestion for mandatory annual registration of each VMS product sold in US, consumer health industry stakeholders’ schism now extends to agency suggestion that Congress clarify its regulatory authority over supplement manufacturing and marketing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts